From: Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance
 | Isolate Phenotypes (%) a |  | ||
---|---|---|---|---|
Drug | S | I | R | Total |
 | Protease Inhibitors |  | ||
Amprenavir (APV) | 63 | 26 | 11 | 495 |
Atazanavir (ATV) | 49 | 29 | 22 | 200 |
Indinavir (IDV) | 53 | 26 | 21 | 502 |
Lopinavir (LPV) | 46 | 22 | 32 | 320 |
Nelfinavir (NFV) | 39 | 28 | 33 | 526 |
Ritonavir (RTV) | 50 | 20 | 30 | 473 |
Saquinavir (SQV) | 61 | 18 | 21 | 509 |
Tipranavir (TPV) | 78 | 11 | 11 | 47 |
 | Nucleoside/Nucleotide RT Inhibitors |  | ||
Lamivudine (3TC) | 29 | 18 | 53 | 244 |
Abacavir (ABC) | 28 | 45 | 27 | 237 |
Zidovudine (AZT) | 50 | 23 | 27 | 240 |
Stavudine (d4T) | 53 | 36 | 11 | 242 |
Zalcitabine (ddC) | 39 | 52 | 9 | 161 |
Didanosine (ddI) | 51 | 43 | 6 | 243 |
Emtricitabine (FTC) | 31 | 13 | 56 | 52 |
Tenofovir (TDF) | 65 | 25 | 10 | 167 |
 | Nonnucleoside RT Inhibitors |  | ||
Delavirdine (DLV) | 53 | 20 | 27 | 304 |
Efavirenz (EFV) | 53 | 22 | 25 | 296 |
Nevirapine (NVP) | 43 | 11 | 46 | 307 |